IPO

Mankind Pharma Limited IPO

Mainboard

Pharmaceuticals

Listed On: May 9, 2023 at ₹ 1300.0(NSE)

₹ 14040 /13 Shares

Check Allotment

Price Summary

Last Closing

2,442.00 (126.11%)

52 Week High

2,564.95

52 Week Low

1,683.05

Last Update

19-Sep-2024 3:30 PM

Mankind Pharma Limited IPO Details

25 Apr, 2023

Open Date

27 Apr, 2023

Close Date

03 May, 2023

Allotment Date

09 May, 2023

Listing Date

Issue Price

₹1026-1080 per equity share

Face Value

₹1 Per Equity Share

Listing at Group

BSE, NSE

Registrar

KFin Technologies Limited

List Price

1300.0(NSE)

Listing Date

2023-05-09

Market Lot

13 Shares (₹14,040/-)
sHNI : 195 Shares (₹2,10,600/-)
bHNI : 936 Shares (₹10,10,880/-)

Lead Manager

Kotak Mahindra Capital Company
Axis Capital Limited
IIFL Securities Ltd
Jefferies India Private Limited
J.P. Morgan India Private Limited

Issue Size

40,058,844 shares(aggregating up to ₹4,326.36 Cr Offer for Sale)

Retail Portion

35% (Number of Retail Applications : 10,78,500 Approx),
(Number of sHNI Applications : 10,270 Approx),
(Number of bHNI Applications : 20,540 Approx)

Subscription

15.32 times

IPO Docs

DRHP RHP ANCHOR

Mankind Pharma Limited IPO Subscription Details

As onQIBNII
bNII   sNII		RetailTotal
Shares Offered / Reserved8,011,7696,008,827
4,005,885    2,002,942		14,020,59628,041,192
Day 1 - 25-04-23 05:00 PM0.08 x0.33
0.37 x   0.25 x		0.10 x0.14 x
Day 2 - 26-04-23 05:00 PM1.86 x1.02
1.21 x   0.64 x		0.25 x0.87 x
Day 3 - 27-04-23 05:00 PM49.16 x3.80
4.99 x   1.41 x		0.92 x15.32 x
Total No. of Applications: 4,62,790 (Approx)

Mankind Pharma Limited Valuations

Earnings Per Share (EPS)

₹33.2/-

P/E Ratio

32.5

RoNW

27.7%

Net Asset Value (NAV) - As on 31.12.22

₹178.38

Mankind Pharma Limited Company Financials All values are in ₹ Cr.

31-Dec-2231-Mar-2231-Mar-2131-Mar-20
Assets9,273.759,147.746,372.635,073.29
Revenue6,777.827,977.586,385.385,975.65
Profit After Tax1,015.981,452.961,293.031,056.15

About The Company

Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations across various acute and chronic therapeutic areas and several consumer healthcare products.

The company has over 36 brands, including Manforce (Rx), Moxikind-CV, Amlokind-AT, Unwanted-Kit, Candiforce, Gudcef, Glimestar-M, Prega News, Dydroboon, Codistar, Nurokind-Gold, Nurokind Plus-RF, Nurokind-LC, Asthakind-DX, Cefakind, Monticope, Telmikind-H, Telmikind, Gudcef-CV, and Unwanted-72, among these.

The company has its presence in several acute and chronic therapeutic areas in India, including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins/minerals/nutrients, and respiratory.

Mankind Pharma has one of the largest distribution networks of medical representatives in the Indian pharmaceutical market (IPM). Over 80% of doctors in India prescribed their formulations and has been ranked number 4th in terms of domestic sales during the Financial Year 2022.

The company has been awarded The Best of Bharat Awards 2022 by exchange4media in the year 2022, Silver Medal from National Awards for Manufacturing Competitiveness Assessment 2021 instituted by International Research Institute for Manufacturing, and Silver Award for Good Health Brand at IHW Awards 2021 in the year 2021, Best Condom Brand of the Year award at Sex Brand Awards Pharma OTC Company of the Year Award at Pharma Excellence Awards 2018, Award for Best Design in Healthcare at Healthcare Leadership Awards 2017, and Amity HR Excellence Award for Performance Management at the 8th Global HR Summit 2011.

Read More

Mankind Pharma Limited - Peers Comparison

P/B RatioP/E RatioRoNWNet Worth
Mankind Pharma6.0532.527.7%7,977
Sun Pharma4.5029.814.0%38,654
Cipla Limited3.3627.813.2%21,763
Zydus Lifesciences3.1425.114.7%15,265
Torrent Pharma8.8743.518.3%8,508
Alkem Lab4.3739.020.7%10.634
J B Chemicals & Pharma7.1040.418.1%2,424
Eris Lifesciences4.1621.423.4%1,347

Mankind Pharma Limited - Promoter(s)

Pre Issue Share Holding: 79.00%

Post Issue Share Holding: 76.50%

Company Promoter(s)

  1. Ramesh Juneja
  2. Rajeev Juneja
  3. Sheetal Arora
  4. Ramesh Juneja Family Trust
  5. Rajeev Juneja Family Trust
  6. Prem Sheetal Family Trust

Mankind Pharma Limited IPO - Issue Objectives

  1. All of the offer proceeds will be received by the selling shareholders in proportion to the offered shares that each selling shareholder sold as part of the offer; the company will not receive any of the offer proceeds.

Mankind Pharma Limited IPO - Anchor Investors

Mankind Pharma raises Rs 1,298 crore from anchor investors.

The marquee investors that participated in the offer included Canada Pension Plan, Government of Singapore, Monetary Authority of Singapore, Goldman Sachs, Fiam Group Trust, Blackrock Global Funds, Abu Dhabi Investment Authority, Nomura Funds, Morgan Stanley, and Neuberger Berman Emerging Markets Equity Fund.

Mankind Pharma Limited IPO - FAQs

Ans. Mankind Pharma Limited IPO is a Mainboard IPO. The issue is priced at ₹1026-1080 per equity share. The minimum order quantity is 13 Shares. The IPO opens on Apr 25, 2023, and closes on Apr 27, 2023. KFin Technologies Limited is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.

Ans. The Mankind Pharma Limited IPO opens on Apr 25, 2023 and closes on Apr 27, 2023.

Ans. The size of Mankind Pharma Limited IPO is 40,058,844 shares(aggregating up to ₹4,326.36 Cr Offer for Sale).

Ans. The IPO price band is set between ₹1026-1080 per equity share.

Ans. To apply for Mankind Pharma Limited IPO IPO, follow the steps given below:

  • - Open the IPO Ji App or Website
  • - Find Mankind Pharma Limited IPO in the List of IPOs
  • - Press "Apply" Button
  • - Select Your Demat Account
  • - Select Your Shares Quantity and Submit
  • - Track Your IPO Status

Ans. The share allotment date of Mankind Pharma Limited IPO is May 3, 2023.

Ans. The Mankind Pharma Limited IPO will be listed on May 9, 2023.

Ans. Follow the steps to check the allotment status for Mankind Pharma Limited IPO here.